Table 1.
Association of the patients’ clinical parameters with NLR and PLR
| Clinical parameters | Total | NLR | P | PLR | P | ||
|---|---|---|---|---|---|---|---|
| Low NLR | High NLR | Low PLR | High PLR | ||||
| n = 359 (%) | n = 195 (%) | n = 164 (%) | n = 136 (%) | n = 223 (%) | |||
| Age (year)a | 48.7 ± 12.4 | 48.5 ± 11.5 | 49.0 ± 13.4 | 0.536 | 46.4 ± 12.3 | 50.2 ± 12.3 | 0.006 |
| Sex | |||||||
| Male | 258 (71.87 %) | 137 (70.26 %) | 121 (73.78 %) | 0.459 | 92 (67.65 %) | 166 (74.44 %) | 0.165 |
| Female | 101 (28.13 %) | 58 (29.74 %) | 43 (26.22 %) | 44 (32.35 %) | 57 (25.56 %) | ||
| Tumor location | |||||||
| Tibia/femur | 290 (80.78 %) | 156 (80.00 %) | 134 (81.71 %) | 0.683 | 104 (76.47 %) | 186 (83.41 %) | 0.106 |
| Elsewhere | 69 (19.22 %) | 39 (20.00 %) | 30 (18.29 %) | 32 (23.53 %) | 37 (16.59 %) | ||
| Pathological fracture | |||||||
| Yes | 62 (17.27 %) | 37 (18.97 %) | 25 (15.24 %) | 0.352 | 25 (18.38 %) | 37 (16.59 %) | 0.663 |
| No | 297 (82.73 %) | 158 (81.03 %) | 139 (84.76 %) | 111 (81.62 %) | 186 (83.41 %) | ||
| Tumor size | |||||||
| <8 cm | 201 (55.99 %) | 110 (56.41 %) | 91 (55.49 %) | 0.861 | 76 (55.88 %) | 125 (56.05 %) | 0.975 |
| ≥8 cm | 158 (44.01 %) | 85 (43.59 %) | 73 (44.51 %) | 60 (44.11 %) | 98 (43.95 %) | ||
| ALP | |||||||
| Elevated | 104 (28.97 %) | 48 (24.62 %) | 56 (34.15 %) | 0.047 | 35 (25.74 %) | 69 (30.94 %) | 0.291 |
| Normal | 255 (71.03 %) | 147 (75.38 %) | 108 (65.85 %) | 101 (74.26) | 154 (69.06 %) | ||
| Clinical stageb | |||||||
| I–II | 161 (44.85 %) | 111 (56.92 %) | 50 (30.49 %) | 0.000 | 73 (53.68 %) | 88 (39.46 %) | 0.009 |
| III | 198 (55.15 %) | 84 (43.08 %) | 114 (69.51 %) | 63 (46.32 %) | 135 (60.54 %) | ||
| Metastasis at diagnosis | |||||||
| Present | 132 (36.77 %) | 41 (21.03 %) | 91 (55.49 %) | 0.000 | 33 (24.26 %) | 99 (44.39 %) | 0.000 |
| Absent | 227 (63.23 %) | 154 (78.97 %) | 73 (44.51 %) | 103 (75.74 %) | 124 (55.61 %) | ||
| Post-chemotherapy | |||||||
| Yes | 187 (50.09 %) | 95 (48.72 %) | 92 (56.10 %) | 0.163 | 67 (49.26 %) | 120 (53.81 %) | 0.403 |
| No | 172 (47.91 %) | 100 (51.28 %) | 72 (43.90 %) | 69 (50.74 %) | 103 (46.19 %) | ||
| WBC counts (*109/L)c | 6.20 (1.90–26.68) | 5.04 (1.90–13.00) | 8.01 (3.10–26.68) | 0.000 | 5.71 (1.90–24.02) | 6.64 (2.20–26.68) | 0.027 |
| Neutrophil counts (*109/L)c | 4.16 (0.84–26.07) | 2.91 (0.84–7.40) | 6.50 (2.42–26.07) | 0.000 | 3.47 (0.84–21.93) | 4.88 (1.10–26.07) | 0.000 |
| Lymphocyte counts (*109/L)c | 1.24 (0.09–4.84) | 1.59 (0.61–4.84) | 0.91 (0.09–4.46) | 0.000 | 1.62 (0.54–4.84) | 1.06 (0.09–2.62) | 0.000 |
| Platelet counts (*109/L)c | 183 (18–516) | 183 (26–516) | 175 (18–490) | 0.890 | 141 (26–292) | 225 (18–516) | 0.000 |
| NLR | 3.19 (0.79–74.49) | ||||||
| PLR | 142 (5.4–3111) | ||||||
ALP alkaline phosphatase, WBC white blood cell, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio
aMean ± SD
bClinical stage according to Enneking surgical stage
cMedian (range)